B+
Bull case
25%
Probability
Target price
$5.75
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
CTKB
Cytek BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+64.7
Score
AI commentary
The post-earnings signal is mixed: operating momentum and guidance improved, but losses, adjusted EBITDA, and expense growth weakened. The packet does not confirm a sustained post-release price reaction or post-print analyst revisions; social context is absent. Treat this as a cautious monitoring setup rather than a high-conviction re-rating thesis.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventMixed Q2 2026 earnings follow-upMedium impact
Q2 revenue reached $48.1 million, recurring revenue was $18.5 million, the installed base grew by 142 instruments, and full-year revenue guidance midpoint increased by $1 million. However, net loss widened to $12.2 million and adjusted EBITDA declined to a $1.5 million loss [#SEC-8K-2026-08-05].
2026-11-06catalystOperating-loss and margin pressureHigh impact
Operating expenses increased 15%, general and administrative expense rose 24% due partly to litigation, severance, and personnel costs, and normalized gross margin excluding a one-time tariff refund was 53% versus reported GAAP margin of 59% [#SEC-8K-2026-08-05].
2026-12-31catalystInstalled-base and recurring-revenue conversionHigh impact
Continued instrument placements, new Borealis and Aurora Evo configurations, and recurring revenue reaching 35% of trailing revenue could support future reagent and service growth if adoption persists [#SEC-8K-2026-08-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology